Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Lisdexamfetamine

From PsychonautWiki Archive
Revision as of 05:17, 11 October 2016 by >Kaylee
Jump to navigation Jump to search
Lisdexamfetamine
Chemical Nomenclature
Common names Lisdexamfetamine, Vyvanse, Elvanse
Substitutive name L-lysine-dextroamphetamine
Systematic name (2S)-2,6-Diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
Class Membership
Psychoactive class Stimulant
Chemical class Amphetamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Bioavailability >96.4%[1]
Threshold 10 mg
Light 20 - 30 mg
Common 30 - 60 mg
Strong 60 - 90 mg
Heavy 90 mg +
Duration
Total 10 - 14 hours
Onset 60 - 90 minutes
Come up 30 - 60 minutes
Peak 3 - 5 hours
Offset 4 - 6 hours
After effects 2 - 6 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Alcohol
GHB
GBL
Opioids
Cannabis
Caffeine
Ketamine
Methoxetamine
Psychedelics
Cocaine
DXM
PCP
25x-NBOMe
2C-T-x
5-MeO-xxT
DOx
Tramadol
aMT
MAOIs
Summary sheet: Lisdexamfetamine

Lisdexamfetamine (contracted from L-lysine-dextroamphetamine), also known as Vyvanse, is a central nervous system (CNS) stimulant and dextroamphetamine prodrug of the phenethylamine class and amphetamine class that is used in the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder. Lisdexamfetamine was designed to act as a chemical slow release dextroamphetamine analogue.

Lisdexamfetamine is a Class B/Schedule II substance in the United Kingdom and a Schedule II controlled substance in the United States.

Chemistry

Lisdexamfetamine is an inactive prodrug that is converted in the body to dextroamphetamine, a pharmacologically active compound which is responsible for the drug’s activity. After oral ingestion, lisdexamfetamine is broken down by enzymes in red blood cells to form L-lysine, a naturally occurring essential amino acid, and dextroamphetamine.

Pharmacology

Lisdexamfetamine was developed with the goal of providing a long duration of effect that is consistent throughout the day, with reduced potential for abuse. The attachment of the amino acid lysine slows down the relative amount of dextroamphetamine available to the blood stream. Because no free dextroamphetamine is present in lisdexamfetamine capsules, dextroamphetamine does not become available through mechanical manipulation, such as crushing or simple extraction. A relatively sophisticated biochemical process is needed to produce dextroamphetamine from lisdexamfetamine. As opposed to Adderall, which contains roughly equal parts of racemic amphetamine and dextroamphetamine salts, lisdexamfetamine is a single-enantiomer dextroamphetamine formula.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

While the subjective effects are almost identical to that of amphetamine, lisdexamfetamine is significantly longer in its duration and more consistent in its intensity due to the slow release metabolism. Although this drug is rate-limited in its metabolism, sufficiently high doses are comparable to its instant release counterparts.

Physical effects

Cognitive effects

Lisdexamfetamine shares most of its cognitive effects with other amphetamines, although it is less forceful in its come-up due to the slow release mechanism. It produces a variety of cognitive enhancements associated with stimulants. However, during latter third of the duration, these cognitive enhancements may compete with or be nullified by the accumulated dopamine depletion and its effects.

The most prominent of these cognitive effects generally include:

Visual effects

Toxicity and harm potential

Main articles: Research chemicals § Toxicity and harm potential & Responsible use § Hallucinogens

In rodents and primates, sufficiently high doses of amphetamine cause dopaminergic neurotoxicity, or damage to dopamine neurons, which is characterized by reduced transporter and receptor function. There is no evidence that amphetamine is directly neurotoxic in humans. However, large doses of amphetamine may cause indirect neurotoxicity as a result of increased oxidative stress from reactive oxygen species and autoxidation of dopamine.

A severe amphetamine overdose can result in a stimulant psychosis that may involve a variety of symptoms, such as paranoia and delusions.[64] A Cochrane Collaboration review on treatment for amphetamine, dextroamphetamine, and methamphetamine psychosis states that about 5–15% of users fail to recover completely. According to the same review, there is at least one trial that shows antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis. Psychosis very rarely arises from therapeutic use. It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

Addiction is a serious risk with heavy recreational amphetamine use but is unlikely to arise from typical long-term medical use at therapeutic doses. Compared to other amphetamine pharmaceuticals, lisdexamfetamine may have a lower liability for abuse as a recreational drug. Drug tolerance develops rapidly in amphetamine abuse (i.e., a recreational amphetamine overdose), so periods of extended use require increasingly larger doses of the drug in order to achieve the same effect.

Repeated use of lisdexamfetmine will result in a gradual tolerance proportional to the dosage taken. Patients prescribed this drug often must increase their dosage after a time to maintain its efficacy.

Lisdexamfetamine is a Class B/Schedule II substance in the United Kingdom and a Schedule II controlled substance in the United States

Experience reports

Anecdotal reports which describe this compound within our experience index include:

Additional experience reports can be found here:

See also

References